title: Nivolumab in NSCLC: latest evidence and clinical potential.
abstract: New insight on the interaction between the immune system and tumor has identified the programmed death-1/programmed death-1 ligand pathway to be a key player in evading host immune response. The immune checkpoint modulator, nivolumab (BMS-936558/ONO-4538), is the first PD-1 inhibitor to gain regulatory approval, for the treatment of patients with unresectable melanoma. This review will discuss results from early phase studies of nivolumab in solid tumors including non-small cell lung cancer (NSCLC) as well as studies of nivolumab in combination with chemotherapy, other immune modulators and molecular targeted therapy in patients with NSCLC.
authors.affiliation: Department of Haematology-Oncology, National University Cancer Institute, National University Health System, Singapore.
authors.forename: Raghav
authors.initials: R
authors.lastname: Sundar
authors.affiliation: Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea.
authors.forename: Byoung-Chul
authors.initials: BC
authors.lastname: Cho
authors.affiliation: Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA.
authors.forename: Julie R
authors.initials: JR
authors.lastname: Brahmer
authors.affiliation: Department of Haematology-Oncology, National University Cancer Institute, National University Health System, 1E Kent Ridge Road, NUHS Tower Block Level 7, Singapore 119228.
authors.forename: Ross A
authors.initials: RA
authors.lastname: Soo
keywords: immune checkpoint modulator; nivolumab; non-small cell lung cancer; programmed death-1; programmed death-1 ligand